- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 20, Issue 42, 2014
Current Pharmaceutical Design - Volume 20, Issue 42, 2014
Volume 20, Issue 42, 2014
-
-
Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Authors: Cristina Fillat, Maria Victoria Maliandi, Ana Mato-Berciano and Ramon AlemanyOncolytic viruses (OV) are promising anti-cancer agents, capable of selectively replicating in tumour cells and killing them. Chemotherapy, on the other hand, remains the backbone of current cancer treatment, although it is limited by a narrow therapeutic index, significant toxicity, and frequent acquired resistance. There is an increasing body of evidence on a variety of chemotherapeutic agents that have been shown t Read More
-
-
-
Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Authors: Anne Schaap-Nutt, Dane A. Thyssen, David W. Drell and Frank EntschladenAs the number of novel drugs that have entered the market in oncology has slowed in recent years, there has been a dramatic shift towards new therapeutic approaches. The majority of cancer patients die from metastasis formation, which has prompted the pharmaceutical industry to begin to investigate a new class of agents: anti-metastatics. This review provides an overview of the targets, mechanisms of action, and drug Read More
-
-
-
Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Authors: Lidija Milkovic, Werner Siems, Renate Siems and Neven ZarkovicOxidative stress is often considered as a causative factor in carcinogenesis. In addition, current knowledge recognizes oxidative stress as a mechanism by which various cancer therapies act against cancer. To ameliorate the side effects of cancer therapy, many of the patients suffering from cancer are subject to adjuvant therapy, which often implies antioxidant supplementation. Yet, the benefits of such adjuvant treatm Read More
-
-
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Authors: Huilin Huang, Hengyou Weng, Hui Zhou and Lianghu QuThe onset of cancer is a complex process that is driven by the accumulation of multiple genetic mutations. However, the fact that inhibition of a single oncogene can impair the proliferation and survival of cancer cells due to their “oncogene addiction” provides implications for the so-called “molecular targeted therapy” in cancer treatment. The oncogenic transcription factor c-Myc is overexpressed in many types of cancers, Read More
-
-
-
The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Authors: Tanja Matijevic Glavan and Jasminka PavelicToll-like receptors (TLRs) are a group of transmembrane receptors that recognize molecular motifs of pathogen origin and activate immune response. Although TLRs were first identified in immune system cells, recent studies show they can also be expressed in tumor cells. TLR3 recognizes dsRNA or its synthetic ligand poly (I: C) and is responsible primarily for the defense against viral infections. Recent studies sh Read More
-
-
-
NCRNA Combined Therapy as Future Treatment Option for Cancer
Authors: Cornelia Braicu, Cristina Catana, George A. Calin and Ioana Berindan-NeagoeCancer initiation and progression are governed by a complex multistep process in which successive alterations accumulate in multiple protein-coding and noncoding genes. MicroRNAs are an evolutionarily conserved class of endogenous 19- to 24-nucleotide noncoding RNAs that have been validated as key players in the balance of most cellular processes, including drug resistance. MicroRNAs change the output of protein-co Read More
-
-
-
Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
Authors: Susan B. Kesmodel, Gauri J. Sabnis, Saranya Chumsri and Angela M.H. BrodieAromatase inhibitors (AIs) have become one of the mainstays of treatment of postmenopausal women with hormone receptorpositive breast cancer. However, acquired resistance to treatment continues to be a significant clinical challenge. There is increasing evidence from preclinical studies that activation of growth factor signaling pathways, as well as cross-talk between these pathways and estrogen receptor-alpha si Read More
-
-
-
s Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
The term ribosome-inactivating protein (RIP) is used to denominate proteins mostly of plant origin, which have N-glycosidase enzymatic activity leading to a complete destruction of the ribosomal function. The discovery of the RIPs was almost a century ago, but their usage has seen transition only in the last four decades. With the advent of antibody therapy, the RIPs have been a subject of extensive research especia Read More
-
-
-
A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Authors: Pablo Reguera, Ainhoa Madariaga and Enrique GrandeAlthough grouped under the same name, neuroendocrine tumors comprise a heterogeneous family of neoplasms with a wide range of clinical and biological behaviors and responses to different treatment options. Most of the tumors derived from enterochromaffin cells are indolent or at least not as aggressive as epithelial tumors. However, a small percentage of these tumors have a poor prognosis and highly aggressive histol Read More
-
-
-
Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
More LessOver the past, progress has always been achieved in therapy of various human diseases with the introduction of novel methodologies from basic to clinical research. Recent advances in techniques, especially DNA sequencing and methylation analyses, faster miniaturized proteomics and live cellular stainings, are opening a new era in cancer research. Perhaps the difference this time can be envisaged as the beginning of the l Read More
-
-
-
Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Authors: Davide Melisi, Lorenzo Calvetti, Melissa Frizziero and Giampaolo TortoraPancreatic cancer is the only human malignancy for which patients’ survival has not improved substantially during the past 30 years. Despite advances in the comprehension of the molecular mechanisms underlying pancreatic carcinogenesis, current systemic treatments offer only a modest benefit in tumor-related symptoms and survival. Over the past decades, gemcitabine and its combination with other standard cy Read More
-
-
-
Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Authors: Qingshan Yang, Lisa S. Chen and Varsha GandhiProviral integration site for Moloney murine leukemia virus (Pim) kinases is a potential therapeutic target in both hematological and solid tumors, and is up-regulated in various cancer types. In certain cases, their expression levels are positively correlated with poor clinical outcome. A number of selective Pim kinase inhibitors are under development and a few are in clinical trials. Investigations of the mechanism of actions of th Read More
-
-
-
Curcumin in Combined Cancer Therapy
Authors: Koraljka Gall Troselj and Renata Novak KujundzicThe mechanisms of beneficial preventive and therapeutic effects achieved by traditional and complementary medicine are currently being deciphered in molecular medicine. Curcumin, a yellow-colored polyphenol derived from the rhizome of turmeric (Curcuma longa), influences a wide variety of cellular processes through the reshaping of many molecular targets. One of them, nuclear factor kappa B (NF-ΚB), represents Read More
-
-
-
Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
Authors: Ludimila Cavalcante, David P. Kelsen and Kenneth H. YuDue to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic a Read More
-
-
-
Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Authors: M. Iovino, E. Guastamacchia, V.A. Giagulli, B. Licchelli, E. Iovino and V. TriggianiThe regulation of neurohypophyseal peptides secretion reflects the convergence of a large number of afferent neural pathways on vasopressinergic and oxytocinergic neurons of supraoptic (SON) and paraventricular nuclei (PVN). In addition to afferent input, vasopressin and oxytocin can also exert an autocrine regulation of neuronal activity. In fact, magnocellular neurons (MCNs) of SON and PVN are able to s Read More
-
-
-
The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Authors: Feng Wang, Junsheng Lin and Ruian XuTumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy. Many clinical trials have verified the safety, tolerability, and therapeutic efficacy of TRAIL or TRAIL agonists in patients. However, the resistance to TRAIL in multiple cancer cells resulted in limited treatment response and poor prognosis. In this revi Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 18
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
